View More Recent Stories
-
iRhythm Technologies (IRTC) PT Lowered to $96 at Needham
-
iRhythm Technologies (IRTC) Receives FDA 510(k) Clearance for Design Modifications to Its Zio AT Device
-
iRhythm Technologies (IRTC) Misses Q3 EPS by 68c ; Offers Guidance
-
Oppenheimer Reiterates Outperform Rating on iRhythm Technologies (IRTC)
-
iRhythm Technologies (IRTC) PT Raised to $95 at Truist Securities
-
BTIG Reiterates Buy Rating on iRhythm Technologies (IRTC)
-
iRhythm Technologies (IRTC) Receives FDA 510(k) Clearance
-
iRhythm Technologies (IRTC) PT Lowered to $100 at Baird
-
Goldman Sachs Starts iRhythm Technologies (IRTC) at Neutral
-
iRhythm Technologies (IRTC) PT Raised to $137 at Canaccord Genuity
-
iRhythm Technologies (IRTC) Announces Japanese Regulatory Approval of the Zio ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
-
iRhythm Technologies (IRTC) Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio Monitor
-
iRhythm Technologies (IRTC) Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
-
Oppenheimer Reiterates Outperform Rating on iRhythm Technologies (IRTC)
-
iRhythm Technologies (IRTC) Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain
-
iRhythm Technologies (IRTC) Tops Q2 EPS by 28c; offers guidance
-
iRhythm Technologies (IRTC) Announces CFO Transition
-
iRhythm Technologies (IRTC) PT Lowered to $120 at Baird
-
Wolfe Research Upgrades iRhythm Technologies (IRTC) to Outperform
-
iRhythm Technologies (IRTC) Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation
-
3 MedTech stocks to own for 2024
